-検索条件
-検索結果
検索 (著者・登録者: kotaki & r)の結果全24件を表示しています

EMDB-39370: 
SARS-CoV-2 spike glycoprotein in complex with NT-108 scFv (1-up state)
手法: 単粒子 / : Anraku Y, Kita S, Onodera T, Tadokoro T, Ito S, Adachi Y, Kotaki R, Suzuki T, Hashiguchi T, Takahashi Y, Maenaka K

EMDB-39371: 
SARS-CoV-2 spike glycoprotein in complex with NT-108 scFv (2-up state)
手法: 単粒子 / : Anraku Y, Kita S, Onodera T, Tadokoro T, Ito S, Adachi Y, Kotaki R, Suzuki T, Hashiguchi T, Takahashi Y, Maenaka K

EMDB-39372: 
SARS-CoV-2 spike glycoprotein in complex with NT-108 scFv focused on RBD and NT-108 scFv interface
手法: 単粒子 / : Anraku Y, Kita S, Onodera T, Tadokoro T, Ito S, Adachi Y, Kotaki R, Suzuki T, Hashiguchi T, Takahashi Y, Maenaka K

PDB-8ykg: 
Structure of SARS-CoV-2 spike glycoprotein in complex with NT-108 scFv (1-up state)
手法: 単粒子 / : Anraku Y, Kita S, Onodera T, Tadokoro T, Ito S, Adachi Y, Kotaki R, Suzuki T, Hashiguchi T, Takahashi Y, Maenaka K

PDB-8ykh: 
Structure of SARS-CoV-2 spike RBD in complex with NT-108 scFv
手法: 単粒子 / : Anraku Y, Kita S, Onodera T, Tadokoro T, Ito S, Adachi Y, Kotaki R, Suzuki T, Hashiguchi T, Takahashi Y, Maenaka K

EMDB-42149: 
S1V2-72 Fab bound to EHA2 from influenza B/Malaysia/2506/2004
手法: 単粒子 / : Finney J, Kong S, Walsh Jr RM, Harrison SC, Kelsoe G

PDB-8udg: 
S1V2-72 Fab bound to EHA2 from influenza B/Malaysia/2506/2004
手法: 単粒子 / : Finney J, Kong S, Walsh Jr RM, Harrison SC, Kelsoe G

EMDB-34741: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

EMDB-34742: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11 focused on RBD and NIV-11 interface
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

PDB-8hgl: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

PDB-8hgm: 
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-11
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

EMDB-33820: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 focused on RBD and NIV-8 interface
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

EMDB-33821: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 1)
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

EMDB-33822: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

EMDB-33823: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 focused on RBD and NIV-10 interface
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

EMDB-33824: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 1)
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

EMDB-33825: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 2)
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

EMDB-33826: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 3)
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

EMDB-33827: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 focused on RBD and NIV-13 interface
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

EMDB-33828: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 1)
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

EMDB-33829: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 2)
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

EMDB-33830: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 3)
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

PDB-7yh6: 
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-8
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y

PDB-7yh7: 
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
手法: 単粒子 / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
ムービー
コントローラー
構造ビューア
EMN検索について



wwPDBはEMDBデータモデルのバージョン3へ移行します
